CYLD Protein (Transcript Variant 1) (Myc-DYKDDDDK Tag)
-
- 抗原 See all CYLD 蛋白
- CYLD (Cylindromatosis (Turban Tumor Syndrome) (CYLD))
- 蛋白类型
- Recombinant
- 产品特性
- Transcript Variant 1
-
宿主
- 人
-
资源
- HEK-293 Cells
- 标记
- This CYLD protein is labelled with Myc-DYKDDDDK Tag.
- 应用范围
- Antibody Production (AbP), Standard (STD)
- 产品特性
-
- Recombinant human CYLD (transcript variant 1) protein expressed in HEK293 cells.
- Produced with end-sequenced ORF clone
- 纯度
- > 80 % as determined by SDS-PAGE and Coomassie blue staining
- Top Product
- Discover our top product CYLD 蛋白
-
-
- 应用备注
-
Recombinant human proteins can be used for:
Native antigens for optimized antibody production
Positive controls in ELISA and other antibody assays - 说明
-
The tag is located at the C-terminal.
- 限制
- 仅限研究用
-
- 浓度
- 50 μg/mL
- 缓冲液
- 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10 % glycerol.
- 储存条件
- -80 °C
- 储存方法
- Store at -80°C. Thaw on ice, aliquot to individual single-use tubes, and then re-freeze immediately. Only 2-3 freeze thaw cycles are recommended.
-
- 抗原
- CYLD (Cylindromatosis (Turban Tumor Syndrome) (CYLD))
- 别名
- Cyld (CYLD 产品)
- 别名
- BRSS Protein, CDMT Protein, CYLD1 Protein, CYLDI Protein, EAC Protein, MFT Protein, MFT1 Protein, SBS Protein, TEM Protein, USPL2 Protein, 2010013M14Rik Protein, 2900009M21Rik Protein, C130039D01Rik Protein, mKIAA0849 Protein, cyld Protein, LRRGT00003 Protein, Rp1 Protein, Rp1h Protein, CYLD lysine 63 deubiquitinase Protein, cylindromatosis (turban tumor syndrome), a Protein, CYLD Protein, Cyld Protein, cylda Protein
- 背景
- This gene is encodes a cytoplasmic protein with three cytoskeletal-associated protein-glycine-conserved (CAP-GLY) domains that functions as a deubiquitinating enzyme. Mutations in this gene have been associated with cylindromatosis, multiple familial trichoepithelioma, and Brooke-Spiegler syndrome. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.
- 分子量
- 107.1 kDa
- NCBI登录号
- NP_056062
- 途径
- Apoptosis, Activation of Innate immune Response
-